Canada’s Jamp Creates Dedicated Biosimilars Division
As It Prepares To Launch Alvotech’s Higher-Strength Adalimumab Humira Rival
Canada’s Jamp Pharma has delivered on plans to create a new dedicated biosimilars division as it prepares to launch the recently-approved higher-strength adalimumab biosimilar on which it has partnered with Alvotech.
